<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03946449</url>
  </required_header>
  <id_info>
    <org_study_id>AROAAT2002</org_study_id>
    <secondary_id>2019-000068-86</secondary_id>
    <nct_id>NCT03946449</nct_id>
  </id_info>
  <brief_title>Assessment of Changes in a Novel Histological Activity Scale in Response to ARO-AAT</brief_title>
  <official_title>A Pilot Open Label, Multi-dose, Phase 2 Study to Assess Changes in a Novel Histological Activity Scale in Response to ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of ARO-AAT Injection (also referred to as
      ARO-AAT) on a histological liver disease activity scale in participants with AAT-associated
      liver disease over time. Participants will receive multiple subcutaneous doses of ARO-AAT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 12 participants will be enrolled to receive multiple subcutaneous injections of
      ARO-AAT. All eligible participants will require a pre-dose biopsy completed as part of the
      study within the screening window. All participants will undergo an End of Study (EOS)
      biopsy. Treated participants will be offered the opportunity to continue treatment in an open
      label extension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Over Time in a Histological Liver Disease Activity Scale</measure>
    <time_frame>Baseline and Week 24 (Cohort 1) or Week 48 (Cohort 2); Extension Cohort: Baseline and Extension Week 44</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in Ishak Fibrosis Score</measure>
    <time_frame>Baseline and Week 24 (Cohort 1) or Week 48 (Cohort 2); Extension Cohort: Baseline and Extension Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline In Soluble Liver Z-Alpha-1 Antitrypsin (Z-AAT), Insoluble Liver Z-AAT Levels</measure>
    <time_frame>Baseline and Week 24 (Cohort 1) or Week 48 (Cohort 2); Extension Cohort: Baseline and Extension Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Serum AAT Levels</measure>
    <time_frame>Baseline and Week 24 (Cohort 1) or Week 48 (Cohort 2); Extension Cohort: Baseline and Extension Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time in Hepatic SERPINA1 mRNA Expression (if sufficient sample is available)</measure>
    <time_frame>Baseline and Week 24 (Cohort 1) or Week 48 (Cohort 2); Extension Cohort: Baseline and Extension Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline Over Time in Liver Fibrosis Gene Expression (if scientifically feasible and sufficient sample is available)</measure>
    <time_frame>Baseline and Week 24 (Cohort 1) or Week 48 (Cohort 2); Extension Cohort: Baseline and Extension Week 44</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment</measure>
    <time_frame>Up to Week 24 (Cohort 1) or Week 48 (Cohort 2); Extension Cohort: up to Extension Week 44</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>ARO-AAT Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered on Day 1, Weeks 4 and 16 for a minimum of 3 doses.
Extension Cohort (optional enrollment): Administered every 12 weeks for 4 additional doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARO-AAT Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered on Day 1, Weeks 4, 16, 28 and 40 for a minimum of 5 doses.
Extension Cohort (optional enrollment): Administered every 12 weeks for 4 additional doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARO-AAT Injection</intervention_name>
    <description>solution for subcutaneous (sc) injection</description>
    <arm_group_label>ARO-AAT Cohort 1</arm_group_label>
    <arm_group_label>ARO-AAT Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AATD

          -  Women of childbearing potential must have a negative pregnancy test, cannot be breast
             feeding, and must be willing to use contraception

          -  Willing to provide written informed consent and to comply with study requirements

          -  Non-smoker for at least 1 year

          -  No abnormal finding of clinical relevance at screening

        Exclusion Criteria:

          -  Clinically significant health concerns other than AATD

          -  Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis

          -  Regular use of alcohol within one month prior to Screening

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study involving therapeutic intervention

          -  Use of illicit drugs within 1 year prior to Screening

        Note: additional inclusion/exclusion criteria may apply, per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>626-304-3400</phone>
    <email>medicalmonitor@arrowheadpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Vienna Division of Gastroenterology and Hepatology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Rupprechter</last_name>
      <phone>+43 1 40 400 61570/47080</phone>
      <email>harald.rupprechter@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Mattias Mandorfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Aachen, Anstalt des offentlich</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Kuerten</last_name>
      <phone>+49 (0) 241 80 37921</phone>
      <email>mkuerten@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Angela Breuer</last_name>
      <phone>+49 (0) 241 80 85660</phone>
      <email>angbreuer@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Pavel Strnad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital,University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita P Pye</last_name>
      <phone>+44 (0)121 371 3886</phone>
      <email>Anita.Pye@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Alice Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantina-Irene Nikitopoulou</last_name>
      <phone>+44 1223 256225</phone>
      <email>konstantina-irene.nikitopoulou@addenbrookes.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>William Griffiths, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh, NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH19 3BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Deans</last_name>
      <phone>+44 131 242 1885</phone>
      <email>Andrew.deans@nhslothian.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Gourab Choudhury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

